September 30, 2014 FIRST HALF-YEAR REPORT 2014
|
|
- Calvin Lane
- 8 years ago
- Views:
Transcription
1 September 30, 2014 FIRST HALF-YEAR REPORT 2014 as of June 30, 2014
2 Financial summary YTD* 2014 YTD* 2013 Revenue CHF million Net operating costs CHF million (16.5) (10.5) Net loss CHF million (23.4) (13.6) June 30, 2014 December 31, 2013 Cash, cash equivalents & trade and other receivables CHF million Full-time equivalents number *YTD = year to date January 1, June 30. First Half-Year Report/2014 2
3 3 First Half-Year Report/2014 Financial Report
4 Financial Report Financial Results Six-month period ended June 30, 2014 Balance sheet Funds available for financing the Company s operations amount to CHF million as per June 30, 2014, and include cash and cash equivalents, financial assets and trade and other receivables. This is CHF million lower than on December 31, 2013 (CHF million). Cash decreased primarily due to expenses incurred from ongoing operating activities (CHF million) as well as funds spent on wind-down agreements with suppliers (CHF 5.60 million). In addition, as a result of a settlement agreement in connection with taking over the liabilities of Asklia Holding AG, a payment of CHF 2.00 million was made in the second quarter of 2014 (see note 7). On June 30, 2014, the nominal value of convertible bonds not held by the Company amounted to CHF million. Cytos did not buy back any convertible bonds on the market during the first half year of Revenue Revenue comprising deferred income from license fees paid by Novartis of CHF 0.50 million has been recognized in the first six month of 2014, unchanged from the same period in Net operating costs Net operating costs during the first six months of 2014 amounted to CHF million, compared to CHF million in the same period of the previous year. Compared to the first half-year 2013, research and development costs increased by CHF 5.60 million to CHF million in the first halfyear of 2014 due to wind-down agreements with suppliers (see note 1). Decreased activities in the Phase 2b study, after having announced the negative topline results of clinical trial with CYT003 on April 14, 2014, led to almost the same level of expenditures on the Phase 2b study costs in the first half-year 2014 as in the first half-year General and administrative costs and sales and marketing expenditures combined amounted to CHF 3.86 million. They were CHF 1.00 million higher in the first half-year of 2014 compared to the corresponding half-year of 2013, mainly due to an increase of legal and consulting costs in conjunction with the preparation of a secondary listing on Nasdaq (CHF 0.44 million) prior to the announcement of negative topline results of the Phase 2b clinical trial with CYT003 as well as accruals of wages in connection with winding down key operational activities of Cytos. Other income in the first half-year of 2014 was CHF 1.58 million which is CHF 0.64 million higher than in the first half-year of 2013 (CHF 0.94 million). A part of the provisions made to cover the liabilities that were taken over as a consequence of the acquisition of Asklia in 2002 (see note 7), were released as per June 30, 2014 and amounted to a total of CHF 0.49 million. Such an effect did not occur in the first half year In addition, other income increased in the first half-year 2014 compared to the same period in 2013 due to higher sublease income. Financial income In the first six month of 2014, financial income increased slightly from CHF 0.08 million by TCHF 4 to CHF 0.09 million when compared to the same period in First Half-Year Report/2014 4
5 Financial Report Financial Results Six-month period ended June 30, 2014 Financial expenses Financial expenses were CHF 7.57 million in the first six months of 2014 and CHF 3.64 million in the corresponding period in Key reasons for the higher financial expenses are mainly due to (i) the increase in accrued interest, stemming from the application of the effective interest rate method on the Convertible Bond (CHF 1.16 million) and the first tranche of the convertible loan notes (CHF 0.79 million) as well as (ii) the accrual of interest in the amount of CHF 1.98 million of the second tranche of the convertible loan notes which has been issued on October 21, Net loss Net loss was CHF million in the first half-year of 2014, compared to a net loss of CHF million in the same period in 2013, mainly due to wind-down agreements (see note 1) with suppliers and higher interest expenses in the first half-year Cash burn The gross cash burn for operating activities, as calculated on the cash flow statement, was CHF 3.31 million on average per month during the first six months of 2014, compared to CHF 1.80 million on average per month in the first half-year of First Half-Year Report/2014
6 Financial Report Cytos Biotechnology Ltd and its subsidiary Consolidated Balance Sheets as of in TCHF Note June 30, 2014 December 31, 2013 Non-current assets: Property and equipment, net Investment in associates Total non-current assets Current assets: Prepayments and other assets Trade and other receivables Cash and cash equivalents 9 18,382 39,847 Total current assets 19,323 40,337 Total assets 19,395 40,502 Shareholders equity: Share capital 4 3,053 3,053 Legal reserves 2 2 Additional paid-in capital 263, ,428 Convertible Bond/loan notes: equity component 9,830 9,830 Treasury shares (210) (216) Accumulated deficit (294,336) (270,867) Total shareholders equity (18,164) 4,230 Non-current liabilities: Convertible Bond/loan notes: liability component 25,168 Convertible Bond/loan notes: accrued interest 2,299 Pension liabilities Provisions 7 2,450 Total non-current liabilities ,462 Current liabilities: Trade accounts payable 58 1,492 Other current liabilities Accrued expenses 1,735 3,417 Convertible Bond/loan notes: liability component 11 31,329 Convertible Bond/loan notes: accrued interest 11 3,589 Deferred income Provisions 48 Total current liabilities 36,959 5,810 Total shareholders equity and liabilities 19,395 40,502 See accompanying notes that are an integral part of these condensed consolidated interim financial statements. First Half-Year Report/2014 6
7 Financial Report Cytos Biotechnology Ltd and it subsidiary Consolidated Income Statements Six months ended Six months ended in TCHF Note June 30, 2014 June 30, 2013 Revenue Revenue Research and development (14,183) (8,585) Sales and marketing (148) (176) General and administrative (3,716) (2,685) Other income 1, Net operating costs (16,464) (10,503) Operating loss (15,964) (10,003) Financial income Financial expense (7,568) (3,640) Loss before deferred tax (23,444) (13,559) Tax income Net loss (23,444) (13,559) Consolidated Statements of Comprehensive Income Six months ended Six months ended in TCHF (except for share information) June 30, 2014 June 30, 2013 Net loss Note (23,444) (13,559) Items that will not be reclassified to profit or loss: Remeasurement of pension liabilities due to adoption of IAS19R (25) 89 Other comprehensive income (25) 89 Total comprehensive loss (23,469) (13,470) Basic and diluted net loss per share 6 (0.77) (0.61) Weighted average number of shares used in computing basic and diluted net loss per share 30,525,276 22,411,431 See accompanying notes that are an integral part of these condensed consolidated interim financial statements. 7 First Half-Year Report/2014
8 Financial Report Cytos Biotechnology Ltd and its subsidiary Consolidated Condensed Statements of Cash Flows Six months ended Six months ended in TCHF Note June 30, 2014 June 30, 2013 Cash flow from operating activities: Net loss (23,444) (13,559) Depreciation and amortization Impairment of property and equipment 93 Share-based compensation Other cash flow items 6,982 3,798 Changes in assets and liabilities (6,405) (1,625) Net cash used in operating activities (21,869) (10,804) Net cash provided by /(used in) investing activities 188 (36) Net cash provided by financing activities 190 Net decrease in cash and cash equivalents (21,491) (10,840) Net effect of currency translation on cash Cash and cash equivalents, beginning of period 39,847 28,585 Cash and cash equivalents, end of period 18,382 17,813 See accompanying notes that are an integral part of these condensed consolidated interim financial statements. First Half-Year Report/2014 8
9 Financial Report Cytos Biotechnology Ltd and its subsidiary Consolidated Statements of Change in Shareholders Equity Convertible Additional Bond/loan Cumulative Number Share Legal paid-in notes: equity Treasury Accumulated translation in TCHF (except for share information) of shares capital reserves capital component shares deficit adjustments Total January 1, ,411,431 2, ,299 9,119 (224) (239,715) (209) 9,647 Total comprehensive loss (13,470) (13,470) Share-based compensation Share capital issuance cost 118* 118 June 30, ,411,431 2, ,959 9,119 (224) (253,185) (209) (3,163) January 1, ,525,276 3, ,428 9,830 (216) (270,658) (209) 4,230 Total comprehensive loss (23,469) (23,469) Issuance of share capital from Treasury shares 55, Use of Treasury Shares (55,520) (6) 6 Share-based compensation June 30, ,525,276 3, ,497 9,830 (210) (294,127) (209) (18,164) See accompanying notes that are an integral part of these condensed consolidated interim financial statements. *Partial repayment of issuance stamp duty. 9 First Half-Year Report/2014
10 First Half-Year Report/
11 1. Organization Cytos is a public biopharmaceutical company domiciled in Schlieren, Switzerland and is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN. On April 14, 2014 Cytos announced that the Phase 2b study of the Company's lead product CYT003 in patients with moderate to severe allergic asthma did not achieve a statistically significant reduction of the Asthma Control Questionnaire (ACQ) score at week 12 in the target patient population compared to placebo. Patients on placebo and at all dose levels of CYT003 achieved a clinically relevant improvement in their asthma control measured by ACQ. Additional endpoints, including lung function also failed to show a statistically significant difference to placebo. As the study did not reach the pre-defined end points after three months of treatment, the clinical study was un-blinded and, upon full review of the data, terminated. No other compound of Cytos promises near term value creation potential. Cytos carries a substantial amount of debt in the form of senior convertible loan notes issued in 2012 and a subordinated traded bond issued in 2007 and restructured in Both debt instruments become due for repayment in February In total, the debt repayable in February amounts to CHF 46 million, whereas the cash as of June 30, 2014 amounted to CHF 18.7 million. In order to avoid a state of over-indebtedness, the four convertible loan note holders - Abingworth, Amgen, venbio and Aisling - have agreed to subordinate part of their loan notes to ordinary creditors. The subordinated part of the loan notes remains senior to the convertible bonds. On May 5, 2014 Cytos announced a wind-down of key operational activities, in particular related to the development and manufacturing of CYT003. The company executed a mass dismissal of employees to minimize operating costs and is further evaluating the feasibility of a sale of pre-clinical programs and technology assets. The financial outcome of such a potential sale is highly uncertain and it is very unlikely that any proceeds will exceed the subordinated part of the loan notes. Consequently, and as stated in the press release issued on April 14, 2014 and May 5, 2014, the Company does not expect to be able to repay any convertible bonds, which are subordinated to other creditors. Likewise, the Company also does not expect to make any payments to shareholders. The consolidated condensed interim financial statements have been approved for issuance by the Audit Committee on September 24, Basis of preparation Based on facts disclosed in note 1, these consolidated condensed interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting on a non-going concern basis. The assets consist mainly of cash and cash equivalents and the liabilities consist of convertible bonds and convertible loan notes which are continued to be measured at amortized cost using the effective interest method. Therefore, the non-going concern basis applied to the consolidated condensed interim financial statements and the accounting policies used in the preparation of these statements are consistent with those used in the annual financial statements for the year ended December 31, 2013 which were prepared on a going concern basis. The consolidated condensed interim financial statement should be read in conjunction with the an- 11 First Half-Year Report/2014
12 nual financial statements for the year ended December 31, For better readability, the amounts in the Group s financial statements and notes are presented in thousands Swiss francs (TCHF) unless stated otherwise. 3. Seasonality Operating costs and revenue are not exposed to substantial seasonal variations. However, revenue from biotech companies may vary significantly throughout the year, since revenue is often linked to up-front payments, milestone and license payments, as well as payments for delivery of drug substances, which occur sporadically. 4. Shareholders equity Options In the first half-year 2014, 55,520 options have been exercised with an exercise price of CHF The Shares needed for this exercise were taken from the Treasury Shares (TCHF 5.55). From the exercise of these options a cash inflow of TCHF has been accounted for (agio: TCHF ). 5. Segment and geographic information Business segment The Group operates in one segment solely, focusing on the development and prospective commercialization of a new class of biopharmaceutical products that are intended for use in the treatment and prevention of chronic diseases. The Group s Executive Board reviews the profit or loss of the Group on an aggregated basis. The operations of the Group are managed as a single operating segment. The Group derives its research and collaboration revenues from research and development collaborations with third parties. Geographical segments All revenue are generated in Switzerland. All operating costs, including research and development, sales and marketing, general and administrative, other operating income and expenses arise in Switzerland as well. First Half-Year Report/
13 The Group s geographic information is as follows in TCHF: Additional information: June 30, 2014 December 31, 2013 Total non-current assets* Total liabilities 37,559 36,272 Six months ended Six months ended June 30, 2014 June 30, 2013 Capital expenditure for property and equipment Depreciation and amortization Impairment of property and equipment 93 0 *No adjustments to non-current assets are required as in line with definition of IFRS 8. Analysis of revenue by category: Six months ended Six months ended in TCHF June 30, 2014 June 30, 2013 Revenue from Novartis royalties and licenses Total Net loss per share Basic and diluted net loss per share have been computed based upon the weighted average number of common shares outstanding. Basic net loss per share excludes any dilutive effects of options, shares subject to repurchase, warrants and convertible securities. Neither outstanding options to purchase shares of common stock nor shares resulting from the conversion rights of the bond holders were included in the computation of the dilutive net loss per share as the effect would have been anti-dilutive. 7. Explanation of provisions concerning the "Asklia" litigation As a consequence of the merger of Cytos Biotechnology AG ( Cytos ) with Asklia Holding AG ( Asklia ) in 2002, Cytos assumed a number of provisions for legal claims as well as costs for lawyers, accounting and liquidation of companies. Since the acquisition of and merger with Asklia, most of the provisions have been claimed or reversed to the income statement. Asklia was involved in (i) various litigations and lawsuits arising in the ordinary daily business and (ii) claims regarding representations, warranties and covenants given by Asklia when divesting its business. Some of these Asklia claims and lawsuits were settled. Other cases of legal disputes, involving subsidiaries of Asklia that were divested prior to the acquisition were transferred as part of the divested business. In two of such lawsuits, in which the plaintiffs claimed CHF 1.3 million and CHF 0.6 million, Asklia agreed to indemnify the acquirer of the divested business for all costs the divested company or the acquirer will incur in connection with these proceedings. 13 First Half-Year Report/2014
14 As a consequence of the acquisition of Asklia these liabilities and lawsuits as well as the other pending and threatened lawsuits and claims of Asklia were taken over by Cytos. Cytos was of the opinion that the adequate provisions of CHF 2.5 million that were made as per December 31, 2013 would cover the risks associated with these various claims and pending or threatened lawsuits. On May 1, 2014, a settlement was reached between Cytos and the legal entity that is one of the counterparties of this law suit for which Cytos assumed the liability as mentioned above. Against a payment of CHF 2 million, any liability of or claim against Cytos is settled in full. As a result, the remaining provisions of CHF 0.5 million were reversed and credited to other income. 8. Share option plans The Group regularly grants share options to the members of the Board of Directors, the members of the Executive Board, as well as to the employees and consultants of the Company. The fair value of the options is determined at the grant date, based on the market price, by using the Black-Scholes model. The share options under the stock option plan 2014 ( SOP 2014 ) were granted as per December 20, In the first half year 2014, no further share options were granted. The expenses for the share-based compensation in relation to the granted share options amounted to TCHF 885 for the first six months of 2014 (TCHF 542 for the first six months of 2013). 9. Cash, cash equivalents and financial assets Due to the current low interest rate of fixed deposits, Cytos has not made any investments in financial assets in the first six months of Property and equipment In the first six months of 2014, the Group invested TCHF 20 into IT equipment (six-month period 2013: TCHF 44). The Group owns no properties. First Half-Year Report/
15 11. Current-/non-current liabilities Original Convertible Bond (see next page Restructured Convertible Bond ) In February 2007, the Company issued 2.875% p.a. convertible bonds ( Convertible Bond ) with a nominal value of CHF million, which are listed on the SIX Swiss Exchange under the symbol CYT07 (security number ). The Convertible Bond was initially due for repayment on February 20, 2012, and was convertible into the Company s shares at a conversion price of CHF 175. The Convertible Bond was restructured, and the restructuring became legally binding on March 13, 2012 and is mentioned separately on the next page. The table below shows the status of the original Convertible Bond, including all closing entries as per the original maturity date February 20, The values of the liability component and the equity conversion component were determined upon issuing the Convertible Bond. The fair value of the liability component was calculated by using a market interest rate for an equivalent non-convertible bond. The residual amount, representing the value of the equity conversion option, is included in shareholders equity. Transaction costs associated with the issuance have been allocated proportionally to the liability component and the equity component. The original Convertible Bond recognized in the balance sheet is calculated as follows: TCHF Nominal value of the Convertible Bond issued in February ,000 Equity component (11,788) Transaction costs allocated to liability component (1,811) Liability component on initial recognition 56,401 Interest expense 19,111 Partial repurchase of convertible bonds (38,601) Gain on partial repurchase of liability component of convertible bonds (15,425) Partial repurchase of equity component 2,385 Interest paid (6,703) Liability component as per February 20, ,168 Thereof interest as per February 20, 2012, due on February 20, ,033 Due to the restructuring of the Convertible Bond, the accrued interest as per February 20, 2012, of TCHF 1,033 will be due on February 20, First Half-Year Report/2014
16 Restructured Convertible Bond The Convertible Bond which was issued in 2007 was due for repayment on February 20, However, because Cytos did not have enough financial means to fully repay the Convertible Bond at maturity, it proposed a bond restructuring to the bondholders on November 10, In summary, Cytos proposed to repay half of the outstanding nominal value at par and to postpone the repayment for the remaining half as well as to defer the payment of any interest to February 20, The repayment will be at 150% of par value. In addition, the coupon has been increased from 2.875% p.a. to 5.75% p.a. Furthermore the conversion price has been reduced to CHF In the meantime, the conversion price has been further reduced to CHF 7.32 per share due to the anti-dilution clause. This restructuring became legally binding on March 13, The value of the liability component of the restructured Convertible Bond was determined based on a discount rate of 47.86%. The remaining value has been allocated to the equity component. The Convertible Bond constitutes direct, subordinated (nachrangig) unsecured and unconditional obligations of the issuer. The restructured Convertible Bond recognized in the balance sheet HY/2014 HY/2013 is calculated as follows: TCHF TCHF Nominal value of the restructured Convertible Bond 16,135 16,135 Adjustment to fair value as per February 20, 2012 (7,100) (7,100) Equity component (688) (688) Transaction costs allocated to liability component (115) (115) Liability component on initial recognition at February 20, ,232 8,232 Interest expense 9,227 4,341 Partial repurchase of convertible bonds (1,880) (1,880) Loss on partial repurchase of liability component of convertible bonds Partial repurchase of equity component Liability component on June 30, ,946 11,060 Accrued interest (deferred until February 20, 2015) 2,170 1,113 The total interest expense amounted to CHF 3.52 million and has been recognized as financial expense for the first six months of 2014 (same period in 2013: CHF 2.36 million). In the course of the first half-year of 2014, Cytos Biotechnology Ltd did not buy back any convertible bonds on the market. First Half-Year Report/
17 First tranche of the Convertible loan notes Four investors granted Cytos Biotechnology Ltd convertible loan notes, payable in two equal tranches with a total amount of CHF million. The convertible loan notes (capital and interest) can be converted into shares of the Company, whereby the conversion price is CHF 2.13 for the capital. The first tranche of CHF million was due for payment upon completion of the capital increase and was paid on May 15, For the second tranche of the convertible loan notes of CHF million we refer to the next page, second tranche of the convertible loan notes. The convertible loan notes carry an interest rate of 9% p.a. and are due for repayment at 150% of the nominal value on February 10, In case of a change in controlling interest, the investors can demand the repayment of the convertible loan notes at 190% of the original amount of the convertible loan notes. The value of the liability component of the first tranche of the convertible loan notes was determined based on a discount rate of 61.19%. The remaining value has been allocated to the equity component. As of May 2, 2014 a total amount of CHF 7.00 million was subordinated. This amount includes CHF million of the principle amount of the first and second tranche of the convertible loan note and accrued interests in the amount of TCHF 375. In addition to this, any interest due for the convertible loan notes accruing after April 14, 2014 is subordinated as well. The convertible loan notes recognized in the Balance sheet are HY/2014 HY/2013 calculated as follows: TCHF TCHF Nominal value of the convertible loan notes issued in May 2012* 6,625 6,625 Equity component (3,572) (3,572) Transaction costs allocated to liability component (102) (102) Liability component on initial recognition on May 15, ,951 2,951 Interest expense 4,687 1,969 Liability component on June 30, ,638 4,920 Accrued interest (deferred until February 10, 2015) 1, *Granted by: venbio Global Strategic Fund L.P., Grand Cayman (Cayman Islands) Amgen Investments Ltd., Hamilton (Bermuda) Abingworth Bioventures V L.P., London (UK) Aisling Capital III L.P., New York (USA) The total interest expense amounted to CHF 2.06 million and has been recognized for the first six months as financial expense (same period in 2013: CHF 1.27 million). 17 First Half-Year Report/2014
18 Second tranche of the convertible loan notes Upon completion of enrollment in the ongoing Phase 2b clinical trial with CYT003 in allergic asthma, the Company called the second tranche of CHF million on October 21, The second tranche of the convertible loan notes of CHF million was paid in four different installments between October 29, 2013 and December 10, The convertible loan notes carry an interest rate of 9% p.a. and are due for repayment at 150% of the nominal value on February 10, In case of a change in controlling interest, the investors can demand the repayment of the convertible loan notes at 190% of the original amount of the convertible loan notes. The value of the liability component of the second tranche of the convertible loan notes was determined based on a discount rate of 61.19%. The remaining value has been allocated to the equity component. As of May 2, 2014 a total amount of CHF 7.00 million was subordinated. This amount includes CHF million of the principle amount of the first and second tranche of the convertible loan note and accrued interests in the amount of TCHF 375. In addition to this, any interest due for the convertible loan notes accruing after April 14, 2014 is subordinated as well. The convertible loan notes recognized in the balance sheet are calculated HY/2014 as follows: TCHF Nominal value of the convertible loan notes issued in October and December 2013* 6,625 Equity component (711) Liability component on initial recognition in October and December ,914 Interest expense 1,831 Liability component as per June 30, ,745 Accrued interest (deferred until February 10, 2015) 323 *Granted by: - venbio Global Strategic Fund L.P., Grand Cayman (Cayman Islands) - Amgen Investments Ltd., Hamilton (Bermuda) - Abingworth Bioventures V L.P., London (UK) - Aisling Capital III L.P., New York, NY (USA) The total interest expense amounted to CHF 1.87 million and has been recognized for the first six months of 2014 as Financial expense. First Half-Year Report/
19 12. Events after balance sheet date There were no subsequent events requiring disclosure after June 30, Disclaimer Cautionary Statement regarding Forward-looking Statements: Certain statements in this quarterly report, including but not limited to statements, estimates and projections of future trends and of the anticipated future performance of Cytos Biotechnology Ltd and its subsidiary (together the Group ), constitute forwardlooking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause the actual results, performance or achievement of the Group, or industry results, to differ materially from any future results, performance or achievement implied by such forward-looking statements. The forward-looking statements are based on the Group s current beliefs and assumptions regarding a large number of factors affecting its business. Such beliefs and assumptions are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of the Group. There can be no assurance that: (i) the Group has correctly measured or identified all of the factors affecting its business or the extent of their likely impact, (ii) the publicly available information with respect to these factors on which the Group s analysis is based is complete or accurate, (iii) the Group s analysis is correct or (iv) the Group s strategy, which is based in part on this analysis, will be successful. Factors which affect the Group s business include, but are not limited to, (i) general market, governmental and regulatory trends, (ii) competitive pressures, (iii) technological developments, (iv) effectiveness and safety of the Group s technology and therapeutics, (v) uncertainty regarding outcome of clinical trials and regulatory approval process, (vi) management changes, (vii) changes in the market in which the Group operates, and (viii) changes in the financial position or creditworthiness of the Group s customers and partners. 19 First Half-Year Report/2014
20 Stock exchange listings at SIX Swiss Exchange Registered shares: Swiss Security No , SIX:CYTN Convertible Bond 2012: Swiss Security No , SIX:CYT07 Share register Aktienregister Cytos Biotechnology Ltd c/o Nimbus AG Postfach CH-8866 Ziegelbrücke (Switzerland) Capital structure Number of registered shares (nominal value CHF 0.10) 30,525,276 Conditional capital CHF 1,526, Authorized capital CHF 1,526, Free float 100% Contact Harry Welten, MBA Chief Financial Officer Tel.: harry.welten@cytos.com Cytos is a public biopharmaceutical company domiciled in Schlieren, Switzerland and is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN. Cytos was founded in 1995 as a spin-off from the Swiss Federal Institute of Technology (ETH) in Zurich. First Half-Year Report/
21
July 23, 2015 FIRST HALF-YEAR REPORT 2015
July 23, 2015 FIRST HALF-YEAR REPORT 2015 as of June 30, 2015 Financial summary YTD* 2015 YTD* 2014 Revenue CHF million 4.5 0.5 Net operating costs CHF million (2.3) (16.5) Net income/(loss) CHF million
More informationExpressed in Canadian Dollars - Unaudited
Hatch Interactive Technologies Corp. (Formerly Tosca Resources Corp.) Consolidated Interim Financial Report For the three and nine month periods ended August 31, 2015 Expressed in Canadian Dollars - Unaudited
More informationDATA GROUP LTD. ANNOUNCES SECOND QUARTER FINANCIAL RESULTS FOR 2015
For Immediate Release DATA GROUP LTD. ANNOUNCES SECOND QUARTER FINANCIAL RESULTS FOR 2015 SECOND QUARTER HIGHLIGHTS Second quarter 2015 ( Q2 ) Revenues of $73.4 million, a decrease of 4.3% year over year
More informationAcuityAds Inc. Condensed Consolidated Interim Financial Statements. Three months ended March 31, 2014 and 2013 (Unaudited)
AcuityAds Inc. Condensed Consolidated Interim Financial Statements Condensed Consolidated Interim Statements of Financial Position March 31, December 31, 2014 2013 Assets Current assets: Cash $ 446,034
More information5N PLUS INC. Condensed Interim Consolidated Financial Statements (Unaudited) For the three month periods ended March 31, 2016 and 2015 (in thousands
Condensed Interim Consolidated Financial Statements (Unaudited) (in thousands of United States dollars) Condensed Interim Consolidated Statements of Financial Position (in thousands of United States dollars)
More informationChesapeake Gold Corp.
Condensed Consolidated Interim Financial Statements June 30, 2015 Second Quarter (unaudited - expressed in thousands of Canadian dollars, except where indicated) Condensed Consolidated Interim Statements
More informationNOTICE OF NO AUDITOR REVIEW OF INTERIM FINANCIAL STATEMENTS
Condensed Interim Consolidated Financial Statements of THE BRICK LTD. For the three months ended March 31, 2013 NOTICE OF NO AUDITOR REVIEW OF INTERIM FINANCIAL STATEMENTS Under National Instrument 51-102,
More informationTower International Reports Solid Third Quarter And Raises Full Year Outlook
FOR IMMEDIATE RELEASE Tower International Reports Solid Third Quarter And Raises Full Year Outlook LIVONIA, Mich., November 3, 2011 Tower International, Inc. [NYSE: TOWR], a leading integrated global manufacturer
More informationNedSense enterprises n.v. Condensed consolidated Interim financial statements
NED NEDSENSE enterprises n.v. NedSense enterprises n.v. Condensed consolidated Interim financial statements 30 June 2012 NedSense enterprises n.v. Half-year Report 2012 (unaudited) Report of the Board
More informationCEMATRIX CORPORATION Consolidated Financial Statements (in Canadian dollars) September 30, 2015
Consolidated Financial Statements September 30, 2015 Management s Responsibility for Financial Reporting and Notice of No Auditor Review of the Interim Consolidated Financial Statements for the Three and
More informationTHERATECHNOLOGIES INC.
Interim Consolidated Financial Statements of (In thousands of Canadian dollars) THERATECHNOLOGIES INC. Table of Contents Page Interim Consolidated Financial Positions 1 Interim Consolidated Statements
More informationRoche Capital Market Ltd Financial Statements 2009
R Roche Capital Market Ltd Financial Statements 2009 1 Roche Capital Market Ltd, Financial Statements Reference numbers indicate corresponding Notes to the Financial Statements. Roche Capital Market Ltd,
More informationRoche Capital Market Ltd Interim Financial Statements 2014
Roche Capital Market Ltd Interim Financial Statements 2014 Roche Capital Market Ltd Interim Financial Statements The Interim Financial Statements have been reviewed by Roche Capital Market Ltd s auditor
More informationRoche Capital Market Ltd Financial Statements 2012
R Roche Capital Market Ltd Financial Statements 2012 1 Roche Capital Market Ltd - Financial Statements 2012 Roche Capital Market Ltd, Financial Statements Reference numbers indicate corresponding Notes
More informationCONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2013 AND 2012.
CONDENSED (Unaudited) (presented in Canadian dollars unless otherwise noted) CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION December 31 As at 2013 2012 Note $ $ Assets Current assets Cash
More informationProperty and equipment, net 1,043 167 Goodwill, net 59,169 - Other intangibles, net 3,005 - Other assets 892 744
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ------------------------------- FORM 10-QSB Quarterly Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly
More informationVII. Consolidated financial statements Credit Suisse (Bank) 281 Report of the Group Auditors. 283 Consolidated statements of income
VII Consolidated financial statements Credit Suisse (Bank) 281 Report of the Group Auditors 283 Consolidated statements of income 284 Consolidated balance sheets 286 Statements of changes in shareholder
More informationNature of operations and basis of preparation (Note 1) Commitments and contingencies (Note 10) Subsequent events (Note 12)
Unaudited Interim Consolidated Financial Statements For the nine months ended September 30, 2005 Contents Interim Consolidated Financial Statements Interim Consolidated Balance Sheets Interim Consolidated
More informationAmadeus Global Travel Distribution, S.A.
Amadeus Global Travel Distribution, S.A. Consolidated Interim Financial Statements as of June 30, 2002, prepared in accordance with International Accounting Standard 34 and Review Report of Independent
More informationConsolidated Balance Sheets
Consolidated Balance Sheets March 31 2015 2014 2015 Assets: Current assets Cash and cash equivalents 726,888 604,571 $ 6,057,400 Marketable securities 19,033 16,635 158,608 Notes and accounts receivable:
More informationRoche Capital Market Ltd Financial Statements 2014
Roche Capital Market Ltd Financial Statements 2014 1 Roche Capital Market Ltd - Financial Statements 2014 Roche Capital Market Ltd, Financial Statements Roche Capital Market Ltd, statement of comprehensive
More information(unaudited expressed in Canadian Dollars)
Condensed Consolidated Interim Financial Statements of CARGOJET INC. For the three month periods ended (unaudited expressed in Canadian Dollars) This page intentionally left blank Condensed Consolidated
More informationcondensed consolidated interim financial statements 2015
January march 2015 condensed consolidated interim financial statements 2015 (unaudited) contents 1. Income Statement 1 2. Statement of Comprehensive Income 2 3. Balance Sheet 3 4. Statement of Changes
More informationHolloway Lodging Corporation. Interim Consolidated Condensed Financial Statements (Unaudited) June 30, 2015 (in thousands of Canadian dollars)
Interim Consolidated Condensed Financial Statements August 12, Management s Report The accompanying unaudited interim consolidated condensed financial statements of Holloway Lodging Corporation (the Company
More informationeqube Gaming Limited Condensed Interim Consolidated Financial Statements For the Three and Nine Months Ended November 30, 2015 (Unaudited)
Condensed Interim Consolidated Financial Statements For the Three and Nine Months Ended November 30, 2015 Notice to Reader The following interim consolidated financial statements and notes have not been
More informationATS AUTOMATION TOOLING SYSTEMS INC.
Interim Consolidated Financial Statements For the period ended June 29, 2014 (Unaudited) (Condensed) Interim Consolidated Statements of Financial Position (in thousands of Canadian dollars unaudited) June
More informationFINANCIAL SUPPLEMENT December 31, 2015
FINANCIAL SUPPLEMENT December 31, 2015 Monster Worldwide, Inc. (together with its consolidated subsidiaries, the Company, Monster, we, our or us ) provides this supplement to assist investors in evaluating
More informationCHINA ENERGY ENGINEERING CORPORATION LIMITED*
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness
More informationUNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2015
BE SEMICONDUCTOR INDUSTRIES N.V. DUIVEN, THE NETHERLANDS UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2015 Contents Unaudited Condensed Interim Consolidated
More information0175/00014699/en Half-Yearly Financial Report GLOBAL DIGITAL SERVICES PLC STC. Correction To:0175/00014529
Correction To:0175/00014529 0175/00014699/en Half-Yearly Financial Report GLOBAL DIGITAL SERVICES PLC STC Corrected Consolidated Half Year Financial Report 9th February 2016 Global Digital Services PLC
More informationQUINSAM CAPITAL CORPORATION INTERIM FINANCIAL STATEMENTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2015 (UNAUDITED AND EXPRESSED IN CANADIAN DOLLARS)
INTERIM FINANCIAL STATEMENTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, (UNAUDITED AND EXPRESSED IN CANADIAN DOLLARS) NOTICE TO READER Under National Instrument 51-102, Part 4, subsection 4.3(3) (a), if
More informationCONSOLIDATED FINANCIAL STATEMENTS
CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (Expressed in Canadian Dollar) and 2007 Index Balance Sheets Statements of Operations, Comprehensive Loss and Deficit Statements of Cash Flows Notes to Financial
More informationTransition to International Financial Reporting Standards
Transition to International Financial Reporting Standards Topps Tiles Plc In accordance with IFRS 1, First-time adoption of International Financial Reporting Standards ( IFRS ), Topps Tiles Plc, ( Topps
More informationConsolidated Statement of Financial Position
INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 30 JUNE 2014 Consolidated Statement of Financial Position in CHF 1,000 Note 30 June 2014 31 December 2013 (unaudited) (audited) Assets Non-current assets
More informationThe Kansai Electric Power Company, Incorporated and Subsidiaries
The Kansai Electric Power Company, Incorporated and Subsidiaries Consolidated Financial Statements for the Years Ended March 31, 2003 and 2002 and for the Six Months Ended September 30, 2003 and 2002 The
More informationVizrt Group AS Reports H1 and Q2 2015 Results
Vizrt Group AS Reports H1 and Q2 2015 Results - 1 - Bergen, Norway, August 31, 2015. Vizrt Group AS. Vizrt today reported its financial results for the second quarter of 2015 and the first six months of
More informationico Therapeutics Inc. Condensed Interim Financial Statements (Unaudited) September 30, 2012 and 2011 (in Canadian dollars)
Condensed Interim Financial Statements (Unaudited) September 30, 2012 and 2011 Balance Sheet (Unaudited) Assets Note September 30, 2012 December 31, 2011 Current assets Cash and cash equivalents 1,478,167
More informationConsolidated Balance Sheets March 31, 2001 and 2000
Financial Statements SEIKAGAKU CORPORATION AND CONSOLIDATED SUBSIDIARIES Consolidated Balance Sheets March 31, 2001 and 2000 Assets Current assets: Cash and cash equivalents... Short-term investments (Note
More informationCORNING INCORPORATED AND SUBSIDIARY COMPANIES CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited; in millions, except per share amounts)
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited; in millions, except per share amounts) Three months ended March 31, 2006 2005 As Restated Net sales $ 1,262 $ 1,050 Cost of sales 689 621 Gross margin
More informationHalf Year 2015 Results
Half Year 2015 Results Letter to shareholders LifeWatch First Half Highlights Revenue growth of 9.1% to USD 52.5 million Above-market growth of over 12% in core monitoring services resulting in market
More informationCARDIOME PHARMA CORP.
Consolidated Financial Statements (Expressed in thousands of United States (U.S.) dollars) (Prepared in accordance with generally accepted accounting principles used in the United States of America (U.S.
More informationInterim Condensed Consolidated Financial Statements NOBLE IRON INC. For the three months ended March 31, 2015 and 2014 (Unaudited)
Interim Condensed Consolidated Financial Statements NOBLE IRON INC. MANAGEMENT S COMMENTS ON UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTICE OF NO AUDITOR REVIEW OF INTERIM FINANCIAL
More informationCondensed Interim Financial Statements Fiscal 2013 First Quarter (Unaudited) For the three months ended July 31, 2012 and 2011
Condensed Interim Financial Statements Fiscal 2013 First Quarter (Unaudited) CRITICAL OUTCOME TECHNOLOGIES INC Page 2 Condensed Interim Financial Statements Table of Contents Notice of No Audit or Review
More informationTitle: Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement)
FASB STAFF POSITION No. APB 14-1 Title: Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement) Date Posted: May 9, 2008 Introduction
More informationMASUPARIA GOLD CORPORATION
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS THREE MONTHS ENDED DECEMBER 31, 2011 and 2010 (expressed in Canadian Dollars) NOTICE TO READERS Under National Instrument 51-102, Part 4.3 (3)(a), if
More information617-444-3913 617-274-7130 AKAMAI REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS
FOR IMMEDIATE RELEASE Contacts: Jeff Young Tom Barth Media Relations Investor Relations Akamai Technologies Akamai Technologies 617-444-3913 617-274-7130 jyoung@akamai.com tbarth@akamai.com AKAMAI REPORTS
More informationDST SYSTEMS, INC. ANNOUNCES THIRD QUARTER 2015 FINANCIAL RESULTS
ANNOUNCES THIRD QUARTER 2015 FINANCIAL RESULTS KANSAS CITY, MO - October 22, 2015 DST Systems, Inc. (NYSE: DST) reported consolidated net income of $75.1 million ($2.08 per diluted share) for the third
More informationIFrS. Disclosure checklist. July 2011. kpmg.com/ifrs
IFrS Disclosure checklist July 2011 kpmg.com/ifrs Contents What s new? 1 1. General presentation 2 1.1 Presentation of financial statements 2 1.2 Changes in equity 12 1.3 Statement of cash flows 13 1.4
More informationCONSOLIDATED STATEMENT OF INCOME
CONSOLIDATED STATEMENT OF INCOME 4 th quarter (a) 3 rd quarter 4 th quarter 2009 Sales 40,157 40,180 36,228 Excise taxes (4,397) (4,952) (4,933) Revenues from sales 35,760 35,228 31,295 Purchases, net
More informationPINK OTC MARKETS. DALRADA FINANCIAL CORPORATION (A Delaware Company)
PINK OTC MARKETS DALRADA FINANCIAL CORPORATION (A Delaware Company) QUARTERLY REPORT: For the Three and Nine Months ended March 31, 2012 and 2011 Contents: Section (I) Dalrada Financial Corporation Quarterly
More informationInd AS 32 and Ind AS 109 - Financial Instruments Classification, recognition and measurement. June 2015
Ind AS 32 and Ind AS 109 - Financial Instruments Classification, recognition and measurement June 2015 Contents Executive summary Standards dealing with financial instruments under Ind AS Financial instruments
More informationQuarterly Report. For the three month period ended. April 30, 2015
Quarterly Report For the three month period ended April 30, 2015 The attached unaudited interim condensed consolidated financial statements have been prepared by Management of International Datacasting
More informationCONSOLIDATED FINANCIAL STATEMENTS
CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2010 BANKERS PETROLEUM LTD. CONSOLIDATED BALANCE SHEETS (Unaudited, expressed in thousands of US dollars) ASSETS June 30 2010 December 31 2009 Current assets
More informationDATA GROUP LTD. ANNOUNCES FIRST QUARTER RESULTS FOR 2014
For Immediate Release DATA GROUP LTD. ANNOUNCES FIRST QUARTER RESULTS FOR 2014 HIGHLIGHTS Q1 2014 First quarter 2014 ( Q1 ) Revenues of 77.9 million, Q1 Gross Profit of 18.8 million and Q1 Net Income of
More informationThe Depository Trust Company
The Depository Trust Company Unaudited Condensed Consolidated Financial Statements as of March 31, 2016 and December 31, 2015 and for the three months ended March 31, 2016 and 2015 THE DEPOSITORY TRUST
More informationFINANCIAL SUMMARY. (All financial information has been prepared in accordance with U.S. generally accepted accounting principles)
FINANCIAL SUMMARY FY2015 First Quarter (April 1, 2014 through June 30, 2014) English translation from the original Japanese-language document TOYOTA MOTOR CORPORATION FY2015 First Quarter Consolidated
More informationInterim Financial Statements 2014
Table of Contents FINANCIAL DISCUSSION FIRST HALF YEAR... 3 CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE SIX MONTHS ENDED 30 JUNE... 6 CONDENSED CONSOLIDATED
More informationKhan Resources Inc. Interim Consolidated Balance Sheets (Expressed in United States dollars) (All dollar amounts are in thousands) (Unaudited)
Interim Consolidated Balance Sheets (All dollar amounts are in thousands) March 31, September 30, 2008 2007 Assets Current Cash $ 32,105 $ 33,859 Accounts receivable 52 47 Prepaid expenses and other assets
More informationNORWEGIAN CRUISE LINE HOLDINGS LTD. CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited, in thousands, except share and per share data)
CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited, in thousands, except share and per share data) Revenue Passenger ticket $ 583,923 $ 490,322 $ 1,400,470 $ 1,257,871 Onboard and other 213,962 184,089 569,479
More informationSEAGATE TECHNOLOGY PLC CONDENSED CONSOLIDATED BALANCE SHEETS
CONDENSED CONSOLIDATED BALANCE SHEETS (In millions) June 28, ASSETS Current assets: Cash and cash equivalents $ 2,259 $ 1,708 Short-term investments 47 480 Restricted cash and investments 4 101 Accounts
More informationWestern Energy Services Corp. Condensed Consolidated Financial Statements September 30, 2015 and 2014 (Unaudited)
Condensed Consolidated Financial Statements September 30, 2015 and 2014 (Unaudited) Condensed Consolidated Balance Sheets (Unaudited) (thousands of Canadian dollars) Note September 30, 2015 December 31,
More informationFALCON OIL & GAS LTD.
Interim Condensed Consolidated Financial Statements Three and Six Months Ended June 30, 2012 and 2011 (Presented in U.S. Dollars) Interim Condensed Consolidated Statements of Financial Position (Unaudited)
More informationAkamai Technologies, Inc.
(Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly
More informationNordic Mining ASA Interim Report per 30 March 2007
Nordic Mining ASA Interim Report per 30 March 2007 Nordic Mining ASA Nordic Mining is a mining company aiming for growth based on integrated activity within exploration, extraction and production of high-end
More informationConsolidated Financial Statements. FUJIFILM Holdings Corporation and Subsidiaries. March 31, 2015 with Report of Independent Auditors
Consolidated Financial Statements FUJIFILM Holdings Corporation and Subsidiaries March 31, 2015 with Report of Independent Auditors Consolidated Financial Statements March 31, 2015 Contents Report of Independent
More informationCondensed Consolidated Interim Financial Statements Three Months Ended May 31, 2013 (Unaudited prepared by Management) (Expressed in Canadian
Condensed Consolidated Interim Financial Statements Three Months Ended May 31, 2013 (Unaudited prepared by Management) (Expressed in Canadian Dollars) 1 Condensed Consolidated Unaudited Interim Financial
More informationHalf Year Report For the six months ended 30 September 2011. Dorchester
Half Year Report For the six months 30 September 2011 Dorchester CONTENTS 01 01 02 03 04 05 06 08 17 17 Summary of activity Financial summary Executive summary - chairman and executive director s report
More informationCapcon Holdings plc. Interim Report 2011. Unaudited interim results for the six months ended 31 March 2011
Capcon Holdings plc Interim Report 2011 Unaudited interim results for the six months ended 31 March 2011 Capcon Holdings plc ("Capcon" or the "Group"), the AIM listed investigations and risk management
More informationSymbility Solutions Inc. Interim Condensed Consolidated Financial Statements (Unaudited) Quarter ended June 30, 2015
Interim Condensed Consolidated Financial Statements (Unaudited) Quarter ended Interim Consolidated Statements of Financial Position (Unaudited - In thousands of Canadian dollars) 2015 As at December 31,
More informationCondensed Interim Consolidated Financial Statements
Condensed Interim Consolidated Financial Statements Unaudited (Expressed in Canadian dollars) NOTICE TO READER: These condensed interim consolidated financial statements have not been reviewed by the Company's
More informationNet cash balances at the year-end were 2.87 million (2014: 2.15 million) and total capital expenditure during the year was 626,000 (2014: 386,000).
Preliminary Announcement for the year ended 30 September 2015 Chairman s Statement The result for the year to 30 September 2015 is a net Profit before Taxation of 1,869,000 (2014: 1,333,000), on Revenues
More informationCondensed Consolidated Statement of Comprehensive Income For the second quarter ended 30 September 2013 (Unaudited)
Condensed Consolidated Statement of Comprehensive Income For the second quarter ended 30 September 2013 (Unaudited) Group Individual Quarter ended Unaudited Unaudited 30 Sep 2012 (Company No: 591898-H)
More informationACER INCORPORATED AND SUBSIDIARIES. Consolidated Balance Sheets
Consolidated Balance Sheets June 30, 2015, December 31, 2014, and (June 30, 2015 and 2014 are reviewed, not audited) Assets 2015.6.30 2014.12.31 2014.6.30 Current assets: Cash and cash equivalents $ 36,400,657
More informationChina Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2016
China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2016 1Q16 Added 16,090 New Subscribers 1Q16 Revenue Up 7.8% YOY to RMB165.4 Million ($26.7 Million) 1Q16 Operating
More informationHow To Calculate Cash Flow From Operating Activities
Lawson Software, Inc. 10 Q Quarterly report pursuant to sections 13 or 15(d) Filed on 10/8/2009 Filed Period 8/31/2009 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10 Q
More informationInterim Condensed Consolidated Financial Statements NOBLE IRON INC. For the three months ended March 31, 2014 and 2013 (Unaudited)
Interim Condensed Consolidated Financial Statements NOBLE IRON INC. MANAGEMENT S COMMENTS ON UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTICE OF NO AUDITOR REVIEW OF INTERIM FINANCIAL
More informationHowiexpress
Interim Condensed Consolidated Financial Statements Element Financial Corporation As at and for the three and six months ended ASSETS INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION [unaudited,
More informationFinancial Statement Analysis: An Introduction
Financial Statement Analysis: An Introduction 2014 Level I Financial Reporting and Analysis IFT Notes for the CFA exam Contents 1. Introduction... 3 2. Scope of Financial Statement Analysis... 3 3. Major
More informationKOREAN AIR LINES CO., LTD. AND SUBSIDIARIES. Consolidated Financial Statements
Consolidated Financial Statements December 31, 2015 (With Independent Auditors Report Thereon) Contents Page Independent Auditors Report 1 Consolidated Statements of Financial Position 3 Consolidated Statements
More informationPAYCHEX, INC. REPORTS THIRD QUARTER RESULTS
PAYCHEX, INC. REPORTS THIRD QUARTER RESULTS March 25, 2015 THIRD QUARTER FISCAL 2015 HIGHLIGHTS Total service revenue increased 8% to $693.6 million for the third quarter; 9% for the nine months. Payroll
More informationReport of the Board of Directors
Report of the Board of Directors First Half 2010 In the first half of 2010, NedSense enterprises n.v. (the Company ) has performed on par with expectations, with results strongly improved as compared to
More informationCONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS September 30, 2015 (Unaudited) TSX-V: ANF. www.anfieldnickel.com
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS September 30, 2015 () TSX-V: ANF www.anfieldnickel.com NOTICE OF NO AUDITOR REVIEW The unaudited condensed consolidated interim financial statements,
More informationSUMITOMO DENSETSU CO., LTD. AND SUBSIDIARIES. Consolidated Financial Statements
SUMITOMO DENSETSU CO., LTD. AND SUBSIDIARIES Consolidated Financial Statements Report of Independent Public Accountants To the Board of Directors of Sumitomo Densetsu Co., Ltd. : We have audited the consolidated
More informationCENTURY ENERGY LTD. FORM 51-102F1 MANAGEMENT DISCUSSION AND ANALYSIS FOR THE YEAR ENDED AUGUST 31, 2014
CENTURY ENERGY LTD. FORM 51-102F1 MANAGEMENT DISCUSSION AND ANALYSIS FOR THE YEAR ENDED AUGUST 31, 2014 The following management s discussion and analysis ( MD&A ), prepared as of December 11, 2014, should
More informationID Watchdog, Inc. Management s Discussion and Analysis For the Three and Six Months Ended June 30, 2015 and 2014
ID Watchdog, Inc. Management s Discussion and Analysis For the Three and Six Months Ended Introduction The following discussion and analysis provides information that management believes is relevant to
More informationConsolidated Financial Statements (In Canadian dollars) ACUITYADS INC. Years ended December 31, 2013, 2012 and 2011
Consolidated Financial Statements ACUITYADS INC. KPMG LLP Telephone (416) 228-7000 Yonge Corporate Centre Fax (416) 228-7123 4100 Yonge Street Suite 200 Internet www.kpmg.ca Toronto ON M2P 2H3 Canada To
More informationQuick Reference Guide toJapan's Financial Statements in 2014
CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) For the three months ended 2015 and 2014 This page intentionally left blank. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
More informationPYROGENESIS CANADA INC. AMENDED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED JUNE 30, 2011
PYROGENESIS CANADA INC. AMENDED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED JUNE 30, 2011 The unaudited interim condensed consolidated financial statements of (the Company ) for the three and six
More informationGENWORTH MI CANADA INC.
Condensed Consolidated Interim Financial Statements (In Canadian dollars) GENWORTH MI CANADA INC. Three and six months ended June 30, 2015 and 2014 Condensed Consolidated Interim Statements of Financial
More informationInterim Consolidated Financial Statements (Unaudited)
Interim Consolidated Financial Statements (Unaudited) For the Six Months Ended, NTT FINANCE CORPORATION This document has been translated and reclassified from a part of the Japanese
More informationAddresses. Corporate Equity Partners AG. Subsidiaries. Company s Registered Head Office: Obmoos 4 CH 6301 Zug Switzerland. The Fantastic IP GmbH
Corporate Equity Partners Group 9 Month Financial Statements 2009 Addresses Corporate Equity Partners AG Company s Registered Head Office: Obmoos 4 CH 6301 Zug Switzerland Subsidiaries The Fantastic IP
More informationStatement of Financial Accounting Standards No. 7. Consolidated Financial Statements
Statement of Financial Accounting Standards No. 7 Statement of Financial Accounting Standards No. 7 Consolidated Financial Statements 30 November 2004 Translated by Wei-heng Lin, Associate Professor (Chung
More informationSAVARIA CORPORATION CONSOLIDATED FINANCIAL STATEMENTS AS AT DECEMBER 31, 2014 AND 2013
SAVARIA CORPORATION CONSOLIDATED FINANCIAL STATEMENTS AS AT DECEMBER 31, 2014 AND 2013 SAVARIA CORPORATION CONSOLIDATED FINANCIAL STATEMENTS As at December 31, 2014 and 2013 TABLE OF CONTENTS PAGE MANAGEMENT'S
More informationAssetCo plc ( AssetCo or the Company ) Results for the six-month period ended 31 March 2012
Issued on behalf of AssetCo plc Date: Friday 29 June 2012 Immediate Release Statement by the Chairman, Tudor Davies AssetCo plc ( AssetCo or the Company ) Results for the six-month period ended 31 March
More informationCondensed Consolidated Statement of Operations and Comprehensive Income (Loss) 3. Condensed Consolidated Balance Sheet 4
CONSOLIDATED FINANCIAL STATEMENTS For the fiscal year ended March 31, 2014 INDEX Page Condensed Consolidated Statement of Operations and Comprehensive Income (Loss) 3 Condensed Consolidated Balance Sheet
More informationANTIBE THERAPEUTICS INC. CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2013
ANTIBE THERAPEUTICS INC. CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2013 To the Shareholders of Antibe Therapeutics Inc. INDEPENDENT AUDITORS REPORT We have audited the accompanying consolidated financial
More informationAbbey plc ( Abbey or the Company ) Interim Statement for the six months ended 31 October 2007
Abbey plc ( Abbey or the Company ) Interim Statement for the six months ended 31 October 2007 The Board of Abbey plc reports a profit before taxation of 18.20m which compares with a profit of 22.57m for
More informationABB Annual Report 2006 Financial summary. Power and productivity for a better world
ABB Annual Report 2006 Financial summary Power and productivity for a better world This is ABB Rising demand for energy and its impact on the environment are the defining challenges of this century. ABB
More information! "#$ %&!& "& ' - 3+4 &*!&-.,,5///2!(.//+ & $!- )!* & % +, -).//0)& 7+00///2 *&&.4 &*!&- 7.00///2 )!*.//+ 8 -!% %& "#$ ) &!&.
! "#!""#$%$#$#$"& $'"()*+,$-).,/ 012! "#$ %&!& "& '!(&)!*&%+,-).//0 -#$#3-4' &,'1$1# $!-!(.//0)& +01+///2 *&& - 3+4 &*!&-.,,5///2!(.//+ &!(!-6%(!(.//.$(!(.//0)& 01,///2 //+2% &*!&- 5,0///2 //32%!(.//+
More informationOVID CAPITAL VENTURES INC./ ENTREPRISES OVID CAPITAL INC. CONDENSED INTERIM FINANCIAL STATEMENTS (Unaudited - See Notice to Reader) March 31, 2015
CONDENSED INTERIM FINANCIAL STATEMENTS March 31, MARCH 31, CONTENTS Page NOTICE TO READER 2 FINANCIAL STATEMENTS Unaudited Condensed Interim Statement of Financial Position 3 Unaudited Condensed Interim
More information